HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, K. Articles by Ikehara, S. Search for Related Content PubMed PubMed Citation Articles by Nakamura, K. Articles by Ikehara, S.

Enhancement of Allogeneic Hematopoietic Stem Cell Engraftment and Prevention of GvHD by Intra-Bone Marrow Bone Marrow Transplantation Plus Donor Lymphocyte Infusion

^a First Department of Pathology,
^b Department of Surgery,
^c Transplantation Center,
^d Regeneration Research Center for Intractable Diseases, and
^e Department of Gynecology, Kansai Medical University, Osaka, Japan

Key Words. Bone marrow transplantation • Donor lymphocyte infusion • Intra-bone marrow injection • Graft rejection • Graft-versus-host disease

Correspondence: Susumu Ikehara, M.D., First Department of Pathology, Kansai Medical University, Fumizono-cho, Moriguchi City, Osaka, Japan, 570-8506. Telephone: 81-6-6992-1001 (ext. 2474 or 2475); Fax: 81-6-6992-1219; e-mail: ikehara{at}takii.kmu.ac.jp

We examined the effect of intra-bone marrow (IBM)-bone marrow transplantation (BMT) in conjunction with donor lymphocyte infusion (DLI) on the engraftment of allogeneic bone marrow cells (BMCs) in mice. Recipients that had received 6 Gy of radiation completely rejected donor BMCs, even when IBM-BMT was carried out. However, when BMCs were IBM injected and donor peripheral blood mononuclear cells (PBMNCs) were simultaneously injected intravenously (DLI), donor cell engraftment was observed 7 days after BMT and complete donor chimerism continued thereafter. It is of interest that the cells of recipient origin did not recover, and that the hematolymphoid cells, including progenitor cells (Lin^-/c-kit⁺ cells) in the recipients, were fully reconstituted with cells of donor origin. The cells in the PBMNCs responsible for the donor BMC engraftment were CD8⁺. Recipients that had received 6 Gy of radiation, IBM-BMT, and DLI showed only a slight loss of body weight, due to radiation side effects, and had no macroscopic or microscopic symptoms of graft-versus-host disease. These findings suggest that IBM-BMT in conjunction with DLI will be a valuable strategy for allogeneic BMT in humans.

This article has been cited by other articles:

				J. Fukui, M. Inaba, Y. Ueda, T. Miyake, N. Hosaka, A-H. Kwon, Y. Sakaguchi, M. Tsuda, M. Omae, Y. Kamiyama, et al. Prevention of Graft-Versus-Host Disease by Intra-Bone Marrow Injection of Donor T Cells Stem Cells, June 1, 2007; 25(6): 1595 - 1601. [Abstract] [Full Text] [PDF]

				Y. Koike, Y. Adachi, Y. Suzuki, M. Iwasaki, N. Koike-Kiriyama, K. Minamino, K. Nakano, H. Mukaide, A. Shigematsu, Y. Kiyozuka, et al. Allogeneic Intrabone Marrow-Bone Marrow Transplantation plus Donor Lymphocyte Infusion Suppresses Growth of Colon Cancer Cells Implanted in Skin and Liver of Rats Stem Cells, February 1, 2007; 25(2): 385 - 391. [Abstract] [Full Text] [PDF]

				Y. Suzuki, Y. Adachi, K. Minamino, Y. Zhang, M. Iwasaki, K. Nakano, Y. Koike, and S. Ikehara A New Strategy for Treatment of Malignant Tumor: Intra-Bone Marrow-Bone Marrow Transplantation Plus CD4- Donor Lymphocyte Infusion Stem Cells, March 1, 2005; 23(3): 365 - 370. [Abstract] [Full Text] [PDF]